Skip to content

Finding Gab in the Treatment of Heart Failure in Assiut University Hospital

Comparison of Treatment and Doses of Drugs in Patient With Heart Failure Reduced Ejection Fraction (HFREF) Between Asyut University Hospital and Guidelines of European Society 0f Cardiology (ESC)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03877887
Enrollment
100
Registered
2019-03-18
Start date
2019-03-31
Completion date
2020-05-31
Last updated
2019-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure With Reduced Ejection Fraction

Brief summary

Analyze the epidemiology and outcome of all patients with heart failure with reduced ejection fraction (HFrEF) presented to Asyut university hospital (AUH) and to identify factors associated with mortality and all-cause hospitalization at a duration of 6 months follow-up.

Detailed description

Heart failure (HF) is nowadays an important health problem and associated with high use of resources and healthcare cost, but the prevalence of heart failure is increasing due to better care and treatment of HF and to the aging of the population. Epidemiology of HF is changing and shifting towards a higher prevalence of patients with HF with preserved ejection fraction. Moreover, the outcome of HF is grim. The mortality rate is high and hospitalizations are frequent and associated with worse outcomes. The majority of studies that analyzed HF outcomes have focused on HF hospitalizations. However, in patients with HF, all-cause hospitalizations can affect up to 23-58% of the patients at 1-year follow-up and non-cardiovascular hospitalizations are associated with risk of subsequent mortality similar to cardiovascular hospitalizations. Despite the evidence that all-cause hospitalizations are detrimental in HF patients, few studies have analyzed whether the factors associated with all-cause and HF-hospitalizations are different in HF patients. However, the characteristics and outcome of HF patients are not well described in developing countries like Egypt. Documenting patients' characteristics and the outcome might improve management of comorbidities associated with heart failure patients in Egypt as well as the disease outcome, However, characteristics and outcome of HF patients are not well described in developing countries like Egypt. Documenting patients' characteristics and the outcome might improve management of comorbidities associated with heart failure patients in Egypt as well as the disease outcome, However, characteristics and outcome of HF patients are not well described in developing countries like Egypt. Documenting patients' characteristics and the outcome might improve management of comorbidities associated with heart failure patients in Egypt as well as the disease outcome However, characteristics and outcome of HF patients are not well described in developing countries like Egypt. Documenting patients' characteristics and the outcome might improve the management of comorbidities associated with heart failure patients in Egypt as well as the disease outcome

Interventions

DIAGNOSTIC_TESTecho cardiogram

Assessment of left ventricular systolic and diastolic function

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

\- All patients \> 18 years of age with left ventricular ejection fraction (LVEF) \< 40 % with symptoms and signs of heart failure (according to ESC guidelines of acute and chronic heart failure 2016).

Exclusion criteria

* patients more than 80 years old

Design outcomes

Primary

MeasureTime frameDescription
To find the percentage of patients treated at guidelines recommended dosessix monthsAll patients presented to Assiut university hospital outpatient clinic, inpatient ward and CCU admission with heart failure reduced ejection fraction will be grouped according to Age ( Etiology,risk factors,severity of symptoms (according to NYHA score),hospitalizations , co-morbidity and treatment and doses they received and compare it to guidelines and follow for re-hospitalization and mortality.

Contacts

Primary Contactabanoub shnouda
abanoubshnouda92@gmail.com201270024800
Backup Contactmohamed abdel ghany
201025880990

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026